Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,800 total articles
Zeta Global (ZETA) looks buyable here after a pullback. The company pairs AI-driven consumer intelligence with omnichannel marketing execution; recent results show strong top-line growth and accelerating free cash flow. Valuation is stretched on multiples but reasonable when viewed versus growth and FCF generation. My mid-term trade targets a move …
TrustCo Bank (TRST) is trading near $46 with improving margins, accelerating loan growth and a freshly authorized 2 million-share repurchase (about 11% of shares). Q4 results showed +38% net income and a 22 bp margin expansion. This trade idea targets upside into the mid $50s while controlling downside with a stop below $44.
Oracle is in the middle of an expensive, high-stakes transition into AI-ready cloud infrastructure and even nuclear-backed power projects. The stock is deeply oversold after a sharp drop; this trade proposes a tactical long entry at $145.485 with a $170 target and a $132 stop over a mid-term 45 trading day horizon, balancing a probable bounce with …
Algonquin Power & Utilities (AQN) is trading near recent highs but still offers an attractive risk/reward for a 2026-oriented trade. The company has shifted toward a regulated-utility model, yields roughly 3.96%, and carries a modest valuation on book value - a setup that could re-rate if rate case outcomes and asset monetizations go in management'…
Pagaya Technologies has real operational progress — record revenue, improving net income and positive free cash flow — yet the stock trades below near-term moving averages and with an RSI near 30. That disconnect creates an actionable swing trade: enter at $18.00, stop at $15.50, and a target at $26.00 over ~45 trading days, balancing upside from m…
HCI Group (HCI) offers a constructive risk/reward: robust free cash flow, low leverage, and an upcoming dividend plus Exzeo IPO optionality set up a mid-term (45 trading days) swing trade. Valuation is compelling at roughly a 10x P/E and EV/EBITDA ~3.6. Enter near current levels, keep a tight stop under structural support, and target a re-rate towa…
Adobe (ADBE) is trading near its 52-week low after a sector-wide re-rating on AI fears. Fundamentals remain solid: $9.85B free cash flow, EPS around $17.37, and a market cap near $115B make today's price an attractive entry for investors willing to accept execution and multiple risk. This trade idea sets a precise entry at $280.00, a stop at $255.0…
Snap is an oversold, cash-generative social ad platform trading at roughly $6.08 with a $10.45B market cap. Recent AI integrations and improving ad products give a plausible path to accelerating revenue and margin recovery. This is a mid-term trade idea: enter $6.10, stop $5.50, target $9.00 over ~45 trading days while watching DAU/ARPU and cash me…
CAE has been knocked lower by headline-driven flows and heavier shorting, but the business remains exposed to secular growth in simulation and training (civil aviation, defense, healthcare). At a $9.9B market cap, with a P/E near 32 and a wide runway in adjacent markets, the risk-reward favors a mid-term long from current levels. Entry $30.50, stop…
Medifast is trading with an enterprise value that looks tiny relative to its market capitalization and liquidity metrics. The market appears to be pricing in an extreme deterioration in the business; that offers a defined-risk long trade with upside to the prior range if the company stabilizes coach metrics or posts a clean quarter. Entry at $11.10…
Full Truck Alliance (YMM) looks set for a bounce. Institutional buys, solid top-line growth (Q3 revenue +10.8%), and a cash-heavy balance sheet support a mid-term long. Technicals show dip momentum fading (RSI ~38, MACD histogram turned positive) while shares trade nearer the 52-week low. This trade targets a reclaim toward the mid-$13s with a tigh…
Shake Shack is trading well below its 52-week high and shows durable cash generation and expansion optionality. Valuation is rich on earnings but reasonable on sales and enterprise value. This trade idea outlines a mid-term (45 trading days) buy with a clear entry at $94.00, stop at $84.00 and target at $120.00, balancing upside from multiple catal…
Eaton's electrical-heavy portfolio is benefiting from accelerated data-center power buildouts, smart-grid investment, and vehicle electrification. With ROE above 20%, free cash flow of $3.32B and a manageable debt load, the company can fund organic growth and M&A. Technicals show momentum, but the stock is extended; this trade prescribes a clear en…
Verisk (VRSK) is a high-quality, subscription-driven analytics franchise that produced roughly $1.12B in free cash flow and carries a modest leverage profile. The stock has been punished since mid-2025 amid guidance cuts and growth concerns, trading at $191.19 and an oversold RSI of ~20.7. We see a favorable asymmetric trade: entry at $191.19, stop…
Unilever (UL) trades at $70.87 and is a convenient, liquid way to capture upside from Magnum and the company’s broader premiumization strategy. Strong momentum (RSI 72.8, bullish MACD), a 3.2% dividend yield, and exposure to growing food and personal-care niches support a mid-term long trade: entry $70.87, target $78.00, stop $66.00 (45 trading day…
CRWE is trading near its shorter-term moving averages while showing elevated episodic short volume and an insider buy on 07/23/2024. Liquidity is low and the listing is on OTC, but the technicals and short activity create an asymmetric risk/reward for a disciplined core long. This trade is intended as a position-sized idea for a 180-trading-day hor…
Ocular Therapeutix (OCUL) looks like an asymmetric event trade. With AXPAXLI in large registrational programs, strong enrollment signals, rumors of renewed takeover interest from Sanofi, and stretched bearish sentiment, a positive SOL-1 readout could re-rate the stock. Risk is material - trial failure, financing needs, and reimbursement uncertainty…
Talen Energy (TLN) has just added ~2.9 GW of modern gas capacity, expanded digital infrastructure partnerships, and continues to generate healthy free cash flow. The market is fixated on short-term volatility; this trade buys the structural improvement at $340 with a stop at $320 and a $420 target over 180 trading days.
Bath & Body Works (BBWI) trades at a discounted multiple (P/E ~6.5, P/FCF ~4.8) while generating nearly $1.0B of free cash flow. The business has to repair a misfired adjacencies strategy and navigate litigation headlines, but a refocus on core fragrance and home categories plus expected margin recovery could produce double-digit total returns over…
Bit Digital has quietly transformed from a pure-play miner into a multi-segment AI infrastructure and HPC/data-center operator. The balance sheet and recent M&A give it a runway to capture cloud/AI demand, but negative free cash flow and heavy capex make execution and capital allocation the central risk. This trade idea proposes a measured long wit…
Global Payments (GPN) is trading like it will never grow again: low multiples, oversold technicals, and a dramatic disconnect between cash flow strength and equity price. I prefer a controlled, mid-term swing long at $67.21 with a $63 stop and an $85 target — a trade that captures mean reversion and valuation upside while respecting execution risk.
HEICO (HEI) is being upgraded to Buy. The company combines durable aerospace aftermarket sales, a disciplined M&A cadence and strong free cash flow generation. At $334 per share the growth story is already priced in, but a mid-term trade to $365 offers a favorable risk/reward given solid balance sheet metrics, recent operational momentum and multip…
Valaris (VAL) looks attractive after a multi-phase recovery in offshore demand. With a market cap near $4.1B, a P/E near 10, free cash flow turning positive and an improving technical backdrop, I put a high-conviction long trade on the name. The trade is predicated on a sustained oil price environment that supports dayrates and utilization for floa…
Achieve Life Sciences is a late-stage developer of cytisinicline, a plant-derived smoking-cessation drug with an FDA review window set for mid-2026. With a refreshed balance sheet after a $45M offering, a commercial lead in place and a market cap near $223M, ACHV presents an asymmetric risk-reward ahead of a binary regulatory decision. We call this…
Pharming Group (PHAR) is trading at $17.26 with a market cap of roughly $1.20B. Recent regulatory noise on a pediatric expansion for Joenja® clouds the near-term outlook, but the approved adult label, a recent acquisition that adds late-stage product potential, improving volume patterns, and a manageable capital structure argue for a tactical long.…
